BioXcel net loss widens to $12.69 million in Q1 FY26

BioXcel Therapeutics, Inc.

BioXcel Therapeutics, Inc.

BTAI

0.00
  • BioXcel Therapeutics posted a net loss of USD 12.7 million in first-quarter 2026, widening from a net loss of USD 7.3 million a year earlier.
  • Revenue rose 22.62% to USD 206,000, while cost of goods sold climbed to USD 283,000 from USD 14,000.
  • R&D expenses fell 35.09% to USD 3 million, while SG&A costs increased 26.18% to USD 7.2 million on higher professional fees.
  • Cash and cash equivalents and restricted cash totaled USD 17.2 million at March 31, 2026, down from USD 28.8 million at year-end 2025.
  • FDA accepted a supplemental NDA to expand IGALMI for at-home use, setting a Nov. 14, 2026 PDUFA date, while management said it is evaluating strategic options with MTS Health Partners that could include a sale, merger, collaboration, or licensing deal.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioXcel Therapeutics Inc. published the original content used to generate this news brief on May 15, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.